Search - tctmd.com

Displaying 1 - 20 of 161

Sort: Relevancy | Date

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Volt Pulsed-Field Ablation System Gains FDA Approval

Todd Neale

December 24, 2025

News Daily News

FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement

Michael O'Riordan

December 23, 2025

News Daily News

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

Todd Neale

December 15, 2025

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

FDA Expands Evolut Indication to Include Redo TAVI

News Daily News

FDA Expands Evolut Indications to Include Redo TAVI

Yael L. Maxwell

August 29, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

Advertisement

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Side Effects of Statins Might Be Overstated: CTT Collaboration

January 2026 Dispatch for the CV Team

Volt Pulsed-Field Ablation System Gains FDA Approval

FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

FDA Expands Evolut Indications to Include Redo TAVI

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

FDA Approves Triple Therapy Polypill for High Blood Pressure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content